F-Prime Capital, a global venture capital firm, Novo Holdings, a life science investor, GV, a venture capital firm, and Eight Roads, an investment fund, led a $60.5m Series B round in Invertx, a veterinary therapeutics company, with participation from Anterra Capital, Casdin Capital and Tekla Capital Management. “With the support of several top-tier investors in this latest financing, Invetx is well-capitalized to continue advancing its novel veterinary products towards approval and commercialization. We have demonstrated rapid progress validating our unique mAb platform and built a rich product pipeline with several programs in the pilot phase and a first product candidate being tested in a clinical field study. This financing is a key milestone for Invetx and one that demonstrates the strong commitment of our investors to biotechnology innovation in animal health," said Juergen Horn, Invetx CEO.